Protagonist snags $40M to bring next-gen IBD drugs to clinic
Expanding the oral targeted therapy offerings for GI diseases like IBD, Protagonist Therapeutics plans to go up against the blockbusters like Humira and Remicade
New research project designed to help people living with IBD manage their meds
Curant Health is launching a study with the Meyerhoff Inflammatory Bowel Disease Center of the Johns Hopkins University School of Medicine to test how well counseling from pharmacists can improve the treatment of inflammatory bowel disease. The study will compare medication therapy management to standard care in a large university hospital setting. Project “A.L.I.V.E” (Adherence […]
presented by
The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
BioAtla-BioMotiv licensing deal results in new biotech startup to develop IBD, cancer drugs
There’s a new biotech startup in town: Kodosil Bio. The by-product of a licensing deal between San Diego biologics developer BioAtla and Cleveland-based biotech incubator BioMotiv, the company will focus on development of a monoclonal antibody for inflammatory bowel diseases and cancers. For now, details are pretty scant on the new company. According to a […]